JOHNSON & JOHNSON JNJ
Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company's primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
The Chief Operating Decision Maker (CODM) is the Company's Chief Executive Officer (Principal Executive Officer). The Executive Committee is Johnson & Johnson's senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels. Within the strategic parameters provided by the Executive Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B | $76.45B | $71.89B |
| Cost of revenue | $30.26B | $27.47B | $26.55B | $24.60B | $23.40B | $28.43B | $27.56B | $27.09B | $25.44B | $21.79B |
| Gross profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B | $54.49B | $51.01B | $50.10B |
| R&D | $109.0M | $1.84B | $483.0M | $0 | $0 | — | — | — | — | — |
| SG&A | $23.68B | $22.87B | $21.51B | $20.25B | $20.12B | $22.08B | $22.18B | $22.54B | $21.52B | $20.07B |
| Interest expense | $971.0M | $755.0M | $772.0M | $276.0M | $183.0M | $201.0M | $318.0M | $1.00B | $934.0M | $726.0M |
| Pre-tax income | $32.58B | $16.69B | $15.06B | $19.36B | $19.18B | $16.50B | $17.33B | $18.00B | $17.67B | $19.80B |
| Income tax | $5.78B | $2.62B | $1.74B | $2.99B | $1.38B | $1.78B | $2.21B | $2.70B | $16.37B | $3.26B |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B | $1.30B | $16.54B |
| EPS, basic | 11.13 | 5.84 | 13.88 | 6.83 | 7.93 | 5.59 | 5.72 | 5.70 | 0.48 | 6.04 |
| EPS, diluted | 11.03 | 5.79 | 13.72 | 6.73 | 7.81 | 5.51 | 5.63 | 5.61 | 0.47 | 5.93 |
| Shares, diluted (wtd. avg.) | $2.43B | $2.43B | $2.56B | $2.66B | $2.67B | $2.67B | $2.68B | $2.73B | $2.75B | $2.79B |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $19.71B | $24.11B | $21.86B | $14.13B | $14.49B | $13.98B | $17.30B | $18.11B | $17.82B | $18.97B |
| Short-term investments | $393.0M | $417.0M | $1.07B | $9.39B | $17.12B | $11.20B | $1.98B | $1.58B | $472.0M | $22.93B |
| Receivables | $17.18B | $14.84B | $14.87B | $14.04B | $15.28B | $13.58B | $14.48B | $14.10B | $13.49B | $11.70B |
| Inventory | $14.19B | $12.44B | $11.18B | $10.27B | $10.39B | $9.34B | $9.02B | $8.60B | $8.77B | $8.14B |
| Total current assets | $55.62B | $55.89B | $53.49B | $55.29B | $60.98B | $51.24B | $45.27B | $46.03B | $43.09B | $65.03B |
| Property, plant and equipment | $23.17B | $20.52B | $19.90B | $17.98B | $18.96B | $18.77B | $17.66B | $17.04B | $17.00B | $15.91B |
| Goodwill | $48.77B | $44.20B | $36.56B | $36.05B | $25.44B | $36.39B | $33.64B | $30.45B | $31.91B | $22.80B |
| Other intangibles | $50.40B | $37.62B | $34.17B | $38.49B | $46.39B | $53.40B | $47.64B | $47.61B | $53.23B | $26.88B |
| Total assets | $199.21B | $180.10B | $167.56B | $187.38B | $182.02B | $174.89B | $157.73B | $152.95B | $157.30B | $141.21B |
| Accounts payable | $11.99B | $10.31B | $9.63B | $9.89B | $11.05B | $9.51B | $8.54B | $7.54B | $7.31B | $6.92B |
| Short-term debt | $2.00B | $1.75B | $1.47B | $1.55B | $2.13B | $1.80B | $1.20B | $2.80B | $1.50B | $1.70B |
| Total current liabilities | $54.13B | $50.32B | $46.28B | $55.80B | $45.23B | $42.49B | $35.96B | $31.23B | $30.54B | $26.29B |
| Long-term debt | $39.44B | $30.65B | $25.88B | $26.89B | $29.98B | $32.63B | $26.49B | $27.68B | $30.68B | $22.44B |
| Total liabilities | $117.67B | $108.61B | $98.78B | $110.57B | $108.00B | $111.62B | $98.26B | $93.20B | $97.14B | $70.79B |
| Retained earnings | $168.98B | $155.79B | $153.84B | $128.34B | $123.06B | $113.89B | $110.66B | $106.22B | $101.79B | $110.55B |
| Total equity | $81.54B | $71.49B | $68.77B | $76.80B | $74.02B | $63.28B | $59.47B | $59.75B | $60.16B | $70.42B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $24.53B | $24.27B | $22.79B | $21.19B | $23.41B | $23.54B | $23.42B | $22.20B | $21.06B | $18.77B |
| Depreciation and amortisation | $7.50B | $7.34B | $7.49B | $6.97B | $7.39B | $7.23B | $7.01B | $6.93B | $5.64B | $3.75B |
| Stock-based compensation | $1.35B | $1.18B | $1.16B | $1.14B | $1.14B | $1.00B | $977.0M | $978.0M | $962.0M | $878.0M |
| Capital expenditure | $4.83B | $4.42B | $4.54B | $4.01B | $3.65B | $3.35B | $3.50B | $3.67B | $3.28B | $3.23B |
| Investing cash flow | -$23.59B | -$18.60B | $878.0M | -$12.37B | -$8.68B | -$20.82B | -$6.19B | -$3.17B | -$14.87B | -$4.76B |
| Financing cash flow | -$5.54B | -$3.13B | -$15.82B | -$8.87B | -$14.05B | -$6.12B | -$18.02B | -$18.51B | -$7.67B | -$8.55B |
| Buybacks | $5.95B | $2.43B | $5.05B | $6.04B | $3.46B | $3.22B | $6.75B | $5.87B | $6.36B | $8.98B |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000200406-26-000016.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $138.42B | 35.6x | 8.9% |